503 related articles for article (PubMed ID: 32712042)
1. [Tryptase: A practical guide for the physician].
Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S
Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042
[TBL] [Abstract][Full Text] [Related]
2. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of tryptase in anaphylaxis and mastocytosis.
Schwartz LB
Immunol Allergy Clin North Am; 2006 Aug; 26(3):451-63. PubMed ID: 16931288
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
5. [IgE mediated anaphylaxis in a patient with systemic mastocytosis].
Escande H; Bennani I; Bulai Livideanu C; Uthurriague C; Paul C; Nougué J
Ann Dermatol Venereol; 2013 Oct; 140(10):641-4. PubMed ID: 24090896
[TBL] [Abstract][Full Text] [Related]
6. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
7. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
8. The presence of mast cell clonality in patients with unexplained anaphylaxis.
Gülen T; Hägglund H; Sander B; Dahlén B; Nilsson G
Clin Exp Allergy; 2014 Sep; 44(9):1179-87. PubMed ID: 25039926
[TBL] [Abstract][Full Text] [Related]
9. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.
Quintás-Cardama A; Sever M; Cortes J; Kantarjian H; Verstovsek S
Leuk Lymphoma; 2013 Sep; 54(9):1959-64. PubMed ID: 23278641
[TBL] [Abstract][Full Text] [Related]
11. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
12. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O
J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome.
Sonneck K; Florian S; Müllauer L; Wimazal F; Födinger M; Sperr WR; Valent P
Int Arch Allergy Immunol; 2007; 142(2):158-64. PubMed ID: 17057414
[TBL] [Abstract][Full Text] [Related]
14. [Vulvar oedema revealing systemic mastocytosis].
Deveza E; Locatelli F; Girardin M; Valmary-Degano S; Daguindau E; Aubin F; Humbert P; Pelletier F
Ann Dermatol Venereol; 2015 Nov; 142(11):685-9. PubMed ID: 26003033
[TBL] [Abstract][Full Text] [Related]
15. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L
Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093
[TBL] [Abstract][Full Text] [Related]
16. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
Valent P; Akin C; Arock M
Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674
[TBL] [Abstract][Full Text] [Related]
17. Disease spectrum in patients with elevated serum tryptase levels.
Aberer E; Savic S; Bretterklieber A; Reiter H; Berghold A; Aberer W
Australas J Dermatol; 2015 Feb; 56(1):7-13. PubMed ID: 24575854
[TBL] [Abstract][Full Text] [Related]
18. Clonal mast cell proliferation in pruriginous skin in hypereosinophilic syndrome.
Wiednig M; Beham-Schmid C; Kranzelbinder B; Aberer E
Dermatology; 2013; 227(1):67-71. PubMed ID: 24008407
[TBL] [Abstract][Full Text] [Related]
19. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
20. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.
Bonadonna P; Zanotti R; Pagani M; Bonifacio M; Scaffidi L; Olivieri E; Franchini M; Reccardini F; Costantino MT; Roncallo C; Mauro M; Boni E; Rizzini FL; Bilò MB; Marcarelli AR; Passalacqua G
J Allergy Clin Immunol Pract; 2018; 6(4):1368-1372. PubMed ID: 29258788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
